Search
Enanta Pharmaceuticals Inc
ENTAAdd to Watchlist
13.450USD
+0.040+0.30%
Close 05/18, 16:00（ET）Quotes delayed by 15 min
390.87MMarket Cap
LossP/E TTM
More Details of Enanta Pharmaceuticals Inc Company
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Enanta Pharmaceuticals Inc Info
Ticker SymbolENTA
Company nameEnanta Pharmaceuticals Inc
IPO dateMar 21, 2013
CEOLuly (Jay R)
Number of employees120
Security typeOrdinary Share
Fiscal year-endMar 21
Address4 Kingsbury Avenue
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16176070800
Websitehttps://www.enanta.com/
Ticker SymbolENTA
IPO dateMar 21, 2013
CEOLuly (Jay R)
Company Executives of Enanta Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
856.12K
+1.62%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
369.60K
+0.94%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
24.36K
+13.57%
Mr. Matthew Paul (Matt) Kowalsky, J.D.
Mr. Matthew Paul (Matt) Kowalsky, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
3.59K
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Dr. Bruce L. A. Carter, Ph.D.
Dr. Bruce L. A. Carter, Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Lesley Russell
Dr. Lesley Russell
Independent Director
Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Independent Director
Independent Director
--
--
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
856.12K
+1.62%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
369.60K
+0.94%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
24.36K
+13.57%
Mr. Matthew Paul (Matt) Kowalsky, J.D.
Mr. Matthew Paul (Matt) Kowalsky, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
3.59K
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
18.61M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
12.85%
Farallon Capital Management, L.L.C.
9.55%
Krensavage Asset Management, LLC
9.53%
BlackRock Institutional Trust Company, N.A.
7.18%
Deep Track Capital LP
6.74%
Other
54.14%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
12.85%
Farallon Capital Management, L.L.C.
9.55%
Krensavage Asset Management, LLC
9.53%
BlackRock Institutional Trust Company, N.A.
7.18%
Deep Track Capital LP
6.74%
Other
54.14%
Shareholder Types
Shareholders
Proportion
Investment Advisor
32.07%
Investment Advisor/Hedge Fund
31.53%
Hedge Fund
26.12%
Individual Investor
4.87%
Research Firm
1.31%
Bank and Trust
0.18%
Pension Fund
0.17%
Family Office
0.13%
Insurance Company
0.03%
Other
3.59%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
283
26.50M
91.33%
+1.78M
2025Q4
241
19.84M
81.86%
+1.48M
2025Q3
284
18.36M
116.72%
-107.60K
2025Q2
311
18.46M
118.85%
-252.82K
2025Q1
334
18.72M
123.57%
-7.64M
2024Q4
340
20.02M
119.82%
-1.32M
2024Q3
346
21.33M
132.40%
-905.26K
2024Q2
344
22.26M
134.58%
-675.35K
2024Q1
353
22.93M
127.70%
-4.09M
2023Q4
365
20.62M
117.32%
-18.18K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
3.73M
12.85%
+1.78M
+91.57%
Dec 31, 2025
Farallon Capital Management, L.L.C.
2.77M
9.55%
+650.00K
+30.63%
Dec 31, 2025
Krensavage Asset Management, LLC
2.77M
9.53%
+651.95K
+30.83%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
2.08M
7.18%
+511.48K
+32.55%
Dec 31, 2025
Deep Track Capital LP
1.96M
6.74%
+472.35K
+31.82%
Dec 31, 2025
Acadian Asset Management LLC
885.13K
3.05%
+18.09K
+2.09%
Dec 31, 2025
Luly (Jay R)
856.12K
2.95%
+13.85K
+1.64%
Feb 12, 2026
BlackRock Financial Management, Inc.
790.26K
2.72%
+612.48K
+344.52%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.7%
iShares Health Innovation Active ETF
0.11%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Biotechnology ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Global X Russell 2000 ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.7%
iShares Health Innovation Active ETF
Proportion0.11%
iShares Micro-Cap ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
